• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Bio-Link - Product Pipeline Review - 2012 Product Image

Bio-Link - Product Pipeline Review - 2012

  • ID: 2193974
  • July 2012
  • 22 pages
  • Global Markets Direct

Bio-Link – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Bio-Link - Product Pipeline Review - 2012” provides data on the Bio-Link’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Bio-Link’s corporate website, SEC filings, investor presentations and featured press releases, both from Bio-Link and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bio-Link - Brief Bio-Link overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bio-Link human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles READ MORE >

2
List of Tables 3
List of Figures 3
Bio-Link Snapshot 4
Bio-Link Overview 4
Key Information 4
Key Facts 4
Bio-Link – Research and Development Overview 5
Key Therapeutic Areas 5
Bio-Link – Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products – Monotherapy 8
Bio-Link – Pipeline Products Glance 9
Bio-Link – Early Stage Pipeline Products 9
Pre-Clinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Bio-Link – Drug Profiles 11
Dynamin Inhibitors For Cancer 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Dynamin Modulators 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
IRAP Inhibitors 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Bio-Link – Pipeline Analysis 15
Bio-Link – Pipeline Products by Therapeutic Class 15
Bio-Link – Pipeline Products By Target 16
Bio-Link - Dormant Projects 17
Bio-Link – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Financial Deals Landscape 19
Bio-Link, Deals Summary 19
Bio-Link, Pharmaceuticals & Healthcare, Deal Details 20
Licensing Agreements 20
Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables
Bio-Link, Key Information 4
Bio-Link, Key Facts 4
Bio-Link – Pipeline by Indication, 2012 6
Bio-Link – Pipeline by Stage of Development, 2012 7
Bio-Link – Monotherapy Products in Pipeline, 2012 8
Bio-Link – Pre-Clinical, 2012 9
Bio-Link – Discovery, 2012 10
Bio-Link – Pipeline By Therapeutic Class, 2012 15
Bio-Link - Pipeline By Target, 2012 16
Bio-Link - Dormant Developmental Projects,2012 17
Bio-Link, Other Locations 18
Bio-Link, Deals Summary 19
Centenary Institute of Cancer Medicine and Cell Biology And Bio-Link Enter Into Licensing Agreement With Becton, Dickinson and Company 20

List of Figures
Bio-Link – Pipeline by Indication, 2012 6
Bio-Link – Pipeline by Stage of Development, 2012 7
Bio-Link – Monotherapy Products in Pipeline, 2012 8
Bio-Link – Pipeline By Therapeutic Class, 2012 15

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos